



CONTACT: Trish Cetrone, 925-787-4283, tcetrone@chasepr.com
Julie Chase, 415-710-7108, jchase@chasepr.com
Chase Communications

**SANTEN ANNOUNCES VICE PRESIDENT, CHIEF MEDICAL OFFICER
-- Also Adds Senior Director, Clinical Affairs --**

NAPA, Calif. (June 4, 2008) -- Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) announced that Susan Schneider, M.D., who joined Santen last May as Vice President, Clinical Affairs, has been named Vice President, Chief Medical Officer.

“As an ophthalmologist with extensive expertise in retinal disease, Susan has brought a critically important skill set to Santen,” says Santen President and Chief Executive Officer Adrienne Graves, PhD. “In her new position as CMO, Susan will play an important role in supporting Santen’s global business development initiatives.”

Specifically, Dr. Schneider will provide medical and clinical evaluations of global business development opportunities as well as the coordination of key opinion leader involvement to support Santen’s strategic focus on addressing critical unmet needs in the retinal, glaucoma and dry eye market segments. Dr. Schneider will also provide support for Phase IV clinical studies for Santen’s strategic partner Vistakon Pharmaceuticals, LLC. She will also be responsible for serving as a medical expert for Santen research and development projects and for providing medical and clinical training within Santen on a worldwide basis.

The creation of the CMO position at Santen Inc. is part of the company’s strategy to expand its clinical and business development efforts to further support global expansion in the dry eye, retinal and glaucoma therapeutic segments.

“The U.S. market continues to be an important element of Santen’s global product development and marketing strategy, and this new position will provide additional focus on identifying and bringing novel products into Santen’s global pipeline,” says Schalou Newton, EDM, Santen’s Vice President of Strategic Marketing & Business Development. Currently, Santen Inc. has two innovative compounds in clinical development in the U.S. in the glaucoma and dry eye therapeutic categories.

As part of Santen's dual focus on business and clinical development, the company has hired a Senior Director, Clinical Affairs, Mike Rinehart. Rinehart, who was Santen's Director, Clinical Affairs from 1995 to 2001, brings more than 25 years of experience in pharmaceutical research to his current position. He managed the clinical development program for Santen's first two U.S. Food and Drug Administration (FDA) approved ophthalmic products. Rinehart and Mark Holdbrook, Senior Director Data Management and Biostatistics, will head Santen's Clinical Development Department.

Santen has four FDA-approved drugs currently marketed in the U.S. Since late 2003, Vistakon Pharmaceuticals has had sole U.S. distribution rights for these products: IQIIX[®] (levofloxacin ophthalmic solution) 1.5%, QUIXIN[®] (levofloxacin ophthalmic solution) 0.5%, BETIMOL[®] (timolol ophthalmic solution) 0.25%, 0.5% and ALAMAST[®] (pemirolast potassium ophthalmic solution) 0.1%. Santen continues to have responsibility for manufacturing, clinical and regulatory activities associated with all four of these products.

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a \$900 million global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly-owned Napa, California-based Santen Inc. Santen's global product pipeline includes many more prescription pharmaceuticals in varying clinical trial phases. A detailed listing, as well as additional corporate information, is available online at www.santeninc.com.

#-#-#